Calcium D3 Nycomed tablets chewable with orange flavour

Země: Arménie

Jazyk: angličtina

Zdroj: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktivní složka:

calcium (calcium carbonate), colecalciferol

Dostupné s:

Takeda AS

ATC kód:

առկա չէ (A12AX)

INN (Mezinárodní Name):

calcium (calcium carbonate), colecalciferol

Dávkování:

500mg+ 5mcg(200IU)

Léková forma:

tablets chewable with orange flavour

Jednotky v balení:

(20), (50), (100) in plastic container

Druh předpisu:

OTC

Stav Autorizace:

Registered

Datum autorizace:

2018-03-12

Charakteristika produktu

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Calcium D3 Nycomed 500 mg/200 IU chewable tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One tablet contains:
Calcium carbonate equivalent to 500 mg calcium
Cholecalciferol concentrate (powder form) equivalent to 200 IU (5
microgram) cholecalciferol
(vitamin D3)
Excipients:
Isomalt (E953)
Sucrose
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Chewable tablets with orange flavour.
Round, white and convex tablets. May have small specks.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Prevention and treatment of vitamin D and calcium deficiency.
Vitamin D and calcium supplement as an adjunct to specific
osteoporosis treatment of patients who
are at risk of vitamin D and calcium deficiency.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
_ _
_ADULTS AND ELDERLY _
_Adjunctive therapy in osteoporosis _
One tablet 2-3 times per day
_Calcium and vitamin D deficiency _
One tablet 1-3 times per day
_PAEDIATRIC POPULATION _
_Calcium and vitamin D deficiency (only) _
One tablet 1-2 times per day.
_IMPAIRED RENAL FUNCTION _
Calcium D3 Nycomed tablets should not be used in patients with severe
renal impairment (see section
4.3).
_ _
_IMPAIRED HEPATIC FUNCTION _
No dose adjustment is required.
METHOD OF ADMINISTRATION
Oral. The tablets should be chewed or sucked.
4.3
CONTRAINDICATIONS

Hypersensitivity to the active substances or to any of the excipients
listed in section 6.1

Severe renal impairment (glomerular filtration rate < 30 ml/min/1.73m
2
)

Diseases and/or conditions resulting in hypercalcaemia and/or
hypercalciuria

Renal calculi (nephrolithiasis)

Hypervitaminosis D
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
During long-term treatment, serum calcium levels should be followed
and renal function should be
monitored through measurement of serum creatinine. Monitoring is
especially important in elderly
patients on concomitant treatment with cardiac glycosides or diuretics
(see section 4.5) and in patie